In vivo stable hg-197(m) compounds, method for the production thereof and use thereof in nuclear medical diagnostics and endoradionuclide therapy (theranostics)
AssigneeHelmholtz-Zentrum Dresden-Rossendorf E.V.
InventorsHans-Jürgen PIETZSCH, Martin WALTHER, Thomas WÜNSCHE
Life of this patent
Estimating the term…
Abstract
The present invention relates to in vivo stable 197(m)Hg compounds according to formula (I) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the 197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA 197(m)Hg by electrophilic substitution; and the use of the 197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer.
Claims16
(canceled)
A 197(m)Hg compound according to one of the following formulas (I), (Ia), (Ib) or (Ic)
- wherein each X and each W are independently selected from H, unsubstituted or substituted alkyl groups, alkoxy groups with formula —OR1, amide groups with formula —CON(R1)2, carboxy groups with formula —COOR1, aryl and heteroaryl groups,
- wherein R1 is selected from H, unsubstituted or substituted C1 to C15-alkyl, succinimidyl, aryl or heteroaryl groups,
- wherein Y is selected from substituted dithiocarbamates, substituted thiolates, unsubstituted or substituted aryl or heteroaryl groups,
- wherein Z is selected from CH, S, N, and O,
- wherein Met is selected from Fe, Cr, Mn, Mo, Ru, and Rh.
Dependencies are inferred from the claim text.